

Ref: GLL/BSE/2025-26/Feb -

Date: February 14, 2026

To
The General Manager,
Corporate Relations Department,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, **Mumbai – 400001.**
Maharashtra State, India.
Script Code: 531739

To
The Listing Manager,
The Ahmedabad Stock Exchange Limited
A-2, Kamdhenu Complex, Opp. Sahajanand
College, 120 Feet Ring Road, Panjara Pol,
Ambawadi, **Ahmedabad - 380015.**
Gujarat State, India.
Script Code:

To
The Calcutta Stock Exchange Limited,
#7, Lyons Range, Murgighata,
Dalhousie, **Kolkata - 700001,**
West Bengal State, India.
Scrip Code: 26178

Dear Sir/Madam,

Sub: Outcome of the Board Meeting of Gennex Laboratories Limited – Scrip Code: 531739/GENNEX

Ref: Regulation 29, 33 & 47 of the SEBI (LODR) 'Regulations, 2015.

In just concluded Meeting of Board of Directors, the Board Approved and considered the following items:

1. Unaudited (Standalone and Consolidated) Financial Statements for the Quarter and Nine months ended December 31, 2025 (annexed herewith);
2. Limited review reports from the Statutory Auditor on Unaudited (Standalone and Consolidated) Financial Statements for the Quarter and Nine months ended December 31, 2025 (annexed here with);
3. Appointment of Ms. Khushbu Kachhawa as Additional Director (Non-Executive Independent Women Director) of the Company;
4. Resignation of Ms. Shilpa Bung as Non-Executive Independent Women Director of the Company;
5. Reconstitution of the Audit Committee of the Company;
6. Reconstitution of the Stakeholders Relationship Committee of the Company;
7. Reconstitution of the Nomination & Remuneration Committee of the Company;

We hereby submit that the Board Meeting had commenced at 04:00 PM and concluded at 4.30 PM.

This intimation is also uploaded on the Company website: www.gennexlab.com.

We request you to take the above information on record and acknowledge the receipt of the same.

Thanking you,

Yours faithfully,

For Gennex Laboratories Limited

Digitally signed by Dinesh
Kumar Kejriwal
Date: 2026.02.14 16:37:00
+05'30'

Dinesh Kumar Kejriwal

Company Secretary & Compliance Officer
Membership #A19293

Gennex Laboratories Limited

Office: 'Akash Ganga' 4th Floor, Plot NO.144, Srinagar colony, Hyderabad-500073, T.S. India | Phone: +91-40-67334400 (30 Lines), Fax: +91-40-67334433
Factory: Sy.No.133, IDA Bollaram, Jinnaram Mandal, Sangareddy Dist – 502325, Telangana, India | Tel: +91-08458 279406, Telefax: +91-08454 279516

Info@gennexlab.com, www.gennexlab.com ■ CIN :L24230TG1990PLC011168


GENNEX LABORATORIES LIMITED

CIN: L24230TG1990PLC011168

 REGD. OFF: Survey #133, IDA Bollaram, Jinnaram mandal, Medak District - 502 325, Telanaga State, India.
 UNAUDITED FINANCIAL RESULTS FOR THE QUARTER/NINE MONTHS ENDED 31ST DECEMBER, 2025
 Tel. No.+91-40-67334400-30, Fax: +91-40-67334433, Email: info@gennexlab.com website: www.gennexlab.com

(All amounts in Rs.lakhs except EPES and Ratios)

Statement of Consolidated Unaudited Financial Results for the Quarter and Nine months ended December 31, 2025							(Rs. in lakhs)
Sl. No.	Particulars	Quarter Ended			Nine Months Ended		Year ended
		31.12.2025	30.09.2025	31.12.2024	31.12.2025	31.12.2024	31.03.2025
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Income from Operations						
	(a) Revenue from Operations	4,036.64	3,724.21	3,770.70	11,178.59	9,757.77	13,790.30
	(b) Other operating Income	258.98	205.99	229.94	692.71	659.57	1,043.01
	Total Income from operations (net)	4,295.61	3,930.20	4,000.64	11,871.30	10,417.34	14,833.31
2	Expenses						
	(a) Cost of material consumed	2,995.51	3,055.68	2,862.27	8,433.15	6,753.40	10,058.95
	(b) Purchases of stock-in-trade	-	-	-	-	-	-
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-165.93	-514.61	-94.45	-842.80	-274.53	-350.58
	(d) Employee benefit expense	233.98	183.79	206.03	686.79	626.96	834.69
	(e) Finance Cost	111.35	102.91	84.07	312.16	240.77	199.08
	(f) Depreciation and amortisation expense	51.85	46.50	49.73	148.75	144.76	360.77
	(g) Other expenses	374.63	449.78	311.47	1,246.23	1,181.49	1,575.44
	Total expenses	3,601.39	3,324.05	3,419.12	9,984.28	8,672.84	12,678.35
3	Profit(+)/Loss(-) from operations before exceptional items and tax (1-2)	-	-	-	-	-	-
		694.22	606.15	581.52	1,887.02	1,744.50	2,154.96
4	Exceptional items	30.00	-	-	30.00	-	15.00
5	Profit(+)/Loss(-) before tax (3+4)	664.22	606.15	581.52	1,857.02	1,744.50	2,139.96
6	Tax Expenses for earlier years	-	-	-	-	-	-
7	Current Tax	-65.00	-55.00	-75.00	-205.00	-235.00	-322.00
8	Deferred tax	-	-	-	-	-	-5.47
9	Total Tax expense	-65.00	-55.00	-75.00	-205.00	-235.00	-327.47
10	Net Movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	-	-	-	-	-	-
11	Net Profit for the period from continuing operation (5-9)	599.22	551.15	506.52	1,652.02	1,509.50	1,812.49
12	Total profit(loss) for period	599.22	551.15	506.52	1,652.02	1,509.50	1,812.49
13	Other comprehensive Income net of taxes	-	-	-	-	-	-
14	Net profit(loss) for period	599.22	551.15	506.52	1,652.02	1,509.50	1,812.49
15	Profit Attributable to :						
	Owners of the parent	523.71	503.23	464.38	1,486.09	1,384.06	1,612.30
	Non Controlling Interest	75.51	47.92	42.14	165.93	125.44	200.19
16	Paid-up Equity Share Capital (Face value Rs. 1 each Equity Share)	2,429.48	2,429.48	2,274.47	2,429.48	2,274.47	2,274.47
17	Other Equity						
	Earning Per Equity Share (EPS) (Face value of Rs 1 per Share)						
	(of Rs. 1 each) (not annualised) :						
	(a) Basic	0.216	0.207	0.220	0.612	0.660	0.793
	(b) Diluted	0.216	0.207	0.220	0.612	0.660	0.784

Consolidated Notes:

- The statement of Consolidated unaudited financial results of the Company for the Quarter and Nine Months ended December 31, 2025, has been reviewed by the Audit Committee and approved by the Board of Directors on February 14, 2026. These have been reviewed by the R Pugalia & Co., the Statutory Auditor of the Company, who have issued an unmodified qualified review report.
- The Consolidated unaudited financial results of Gennex Laboratories Limited ('the Company') have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34 'Interim Financial Reporting' Indian Accounting Standards (Ind AS) notified under section 133 of the Companies Act 2013 ('the Act'), read with the Companies (Indian Accounting Standard) Rule, 2015, as amended from time to time and other accounting principles generally accepted in India.
- The Company operating segment is "Bulk Drugs" Manufacturing as its deals mainly with Guaifenesin, Methocarbamol, it also does business outside India. The Company operates in single segment and therefore the Segment Reporting as per AS-17 is not applicable for the Company.
- Previous period's figures have been rearranged / regrouped wherever necessary
- The quarterly unaudited Consolidated Financial results for the Quarter and Nine Month ended December 31, 2025 are available on the Company's Website i.e., www.gennexlab.com and also available on BSE website i.e., www.bseindia.com.

For Gennex Laboratories Limited

 Date: 14.02.2026
 Place: Hyderabad

 Arihant Baid
 Managing Director
 DIN # 01171845

 ARIHANT
 T BAID
 Digitally signed
 by ARIHANT BAID
 Date: 2026.02.14
 16:41:36 +05'30'

R Pugalia & Company
Chartered Accountants
20 E Lake Road Kolkata-700029

Limited Review report on Unaudited Consolidated financial results for quarter and Nine months ended 31thDecember, 2025 of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015.

To
The Board of Directors,
M/s. Gennex Laboratories Limited,
Hyderabad.

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **M/s. Gennex Laboratories Limited** ("the Company") and its share of the net profit/(loss) after tax and total comprehensive income / loss of its Subsidiary for the quarter and Nine months ended December 31, 2025, and for the period from April 01, 2025 to December 31, 2025 ("the Statement") being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. Attention is drawn to the fact that the consolidated figures corresponding quarter and half yearly ended December 31, 2025 as reported in these financial results have been approved by the Company's Board of Directors, but have not been subjected to review.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act, and

consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of Deccan Remedies Limited. (Subsidiary Company)

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standard specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. The accompanying unaudited consolidated financial results includes unaudited interim financial results and other unaudited financial information in respect of 1 Subsidiary, which have been reviewed by other auditors, whose interim financial results excluding consolidation eliminations reflect total revenues of Rs.1224.37 Lakhs, total net Profit before tax of Rs.154.10 for the nine months ended December 31, 2025 as considered in the unaudited consolidated financial results. These unaudited financial results and other unaudited financial information have been approved and furnished to us by the management. Our conclusion, in so far as it relates to the affairs of this Subsidiary, is based solely on such unaudited financial results and other unaudited financial information. According to the information and explanations given to us by the Management, these interim financial results are not material to the Group. Our conclusion on the Statement is not modified in respect of the above matter.

For R PUGALIA & COMPANY
Chartered Accountants
Firm Registration No.318188E

R. Pugalia

RAJEEV KUMAR PUGALIA
Membership No.053972
Place: Kolkata
Date: 14th February, 2026
UDIN 26053972APPGHM2711





GENNEX LABORATORIES LIMITED

CIN: L24230TG1990PLC011168

REGD. OFF: Survey #133, IDA Bollaram, Jinnaram mandal, Medak District - 502 325, Telanagan State, India.
 UNAUDITED FINANCIAL RESULTS FOR THE QUARTER/NINE MONTHS ENDED 31ST DECEMBER, 2025
 Tel. No.+91-40-67334400-30, Fax: +91-40-67334433, Email: info@gennexlab.com website: www.gennexlab.com

(All amounts in Rs.lakhs except EPES and Ratios)

Statement of Standalone Unaudited Financial Results for the Quarter and Nine months ended December 31, 2025							
							(Rs. in lakhs)
Sl. No.	Particulars	Quarter Ended			Nine Months Ended		Year ended
		31.12.2025	30.09.2025	31.12.2024	31.12.2025	31.12.2024	31.03.2025
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Income from Operations						
	(a) Revenue from Operations	2,817.63	2,932.63	2,527.63	8,314.26	7,129.62	9,457.79
	(b) Other operating Income	253.60	204.18	206.96	684.22	635.31	922.13
	Total Income from operations (net)	3,071.23	3,136.81	2,734.59	8,998.48	7,764.93	10,379.92
2	Expenses						
	(a) Cost of material consumed	1,815.30	2,656.90	2,065.63	6,299.17	4,573.34	6,718.15
	(b) Purchases of stock-in-trade		-	-	-	-	-
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	116.40	-694.07	-218.77	-676.47	210.45	-70.14
	(d) Employee benefit expense	208.95	187.64	114.07	584.62	453.70	642.50
	(e) Finance Cost	68.98	55.45	40.81	183.58	104.96	158.45
	(f) Depreciation and amortisation expense	21.25	20.70	19.66	61.82	54.36	76.95
	(g) Other expenses	315.25	386.88	217.15	1,012.39	879.63	1,132.85
	Total expenses	2,546.13	2,613.50	2,238.56	7,465.11	6,276.45	8,658.77
3	Profit(+)/Loss(-) from operations before exceptional items and tax (1-2)	525.10	523.32	496.00	1,533.37	1,488.48	1,721.15
4	Exceptional items	30.00	-	-	30.00	-	15.00
5	Profit(+)/Loss(-) before tax (3+4)	495.10	523.32	496.00	1,503.37	1,488.48	1,706.15
6	Tax Expenses for earlier years	-	-	-	-	-	-
7	Current Tax	-50.00	-70.00	-75.00	-190.00	-235.00	-297.00
8	Deferred tax	-	-	-	-	-	-5.47
9	Total Tax expense	-50.00	-70.00	-75.00	-190.00	-235.00	-302.47
10	Net Movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	-	-	-	-	-	-
11	Net Profit for the period from continuing operation (5-9)	445.10	453.32	421.00	1,313.37	1,253.48	1,403.68
12	Profit(+)/Loss(-) from discontinued operations before tax	445.10	453.32	421.00	1,313.37	1,253.48	1,403.68
13	Tax expense of discontinued operations	-	-	-	-	-	-
14	Net Profit(loss) for the period from discontinued operations	-	-	-	-	-	-
15	Share of Profit(loss) of associates and Joint Ventures accounted for using equity method	-	-	-	-	-	-
16	Total profit(loss) for period	445.10	453.32	421.00	1,313.37	1,253.48	1,403.68
17	Other comprehensive Income net of taxes	-	-	-	-	-	-
18	Net profit(loss) for period	445.10	453.32	421.00	1,313.37	1,253.48	1,403.68
19	Paid-up Equity Share Capital (Face value Rs. 1 each Equity Share)	2,429.48	2,429.48	2,274.47	2,429.48	2,274.47	2,274.48
20	Other Equity	-	-	-	-	-	-
	Earning Per Equity Share (EPS) (Face value of Rs 1 per Share)						
	(of Rs. 1 each) (not annualised) :						
	(a) Basic	0.183	0.187	0.185	0.541	0.550	0.617
	(b) Diluted	0.183	0.187	0.183	0.541	0.550	0.607

Standalone Notes:

- The statement of Standalone unaudited financial results of the Company for the Quarter and Nine Months ended December 31, 2025, has been reviewed by the Audit Committee and approved by the Board of Directors on February 14, 2026. These have been reviewed by the R Pugalia & Co., the Statutory Auditor of the Company, who have issued an unmodified qualified review report.
- The standalone unaudited financial results of Gennex Laboratories Limited ('the Company') have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34 'Interim Financial Reporting' Indian Accounting Standards (Ind AS) notified under section 133 of the Companies Act 2013 ('the Act'), read with the Companies (Indian Accounting Standard) Rule, 2015, as amended from time to time and other accounting principles generally accepted in India.
- The Company operating segment is "Bulk Drugs" Manufacturing as its deals mainly with Guaifenesin, Methocarbamol, it also does business outside India. The Company operates in single segment and therefore the Segment Reporting as per AS-17 is not applicable for the Company.
- Previous period's figures have been rearranged / regrouped wherever necessary
- The quarterly unaudited standalone Financial results for the Quarter and Nine Months ended December 31, 2025 are available on the Company's Website i.e., www.gennexlab.com and also available on BSE website i.e., www.bseindia.com.

For Gennex Laboratories Limited

Date: 14.02.2026
Place: Hyderabad

Arihant Baid
Managing Director
DIN # 01171845

ARIHANT BAID Digitally signed
Date: 2026.02.14
16:41:13 +05'30'

R Pugalia & Company
Chartered Accountants
20 E Lake Road Kolkata-700029

Limited Review report on Unaudited Standalone financial results for the quarter and nine months ended 31thDecember, 2025 of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015.

To
The Board of Directors,
M/s. Gennex Laboratories Limited,
Hyderabad.

We have reviewed the accompanying Statement of Unaudited Standalone financial results of **Gennex Laboratories Limited** for the Quarter and nine months ended December 31, 2025 and for the period from April 01,2025 to December 31, 2025("the statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended.

This statement is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliances with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data, thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as stated in paragraph 3 above nothing has come to our attention, except as stated below, that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For R PUGALIA & COMPANY
Chartered Accountants
Firm Registration No.318188E

Rajeev Kumar Pugalia

RAJEEV KUMAR PUGALIA
Membership No.053972
Place: Kolkata
Date: 14th February, 2026
UDIN: 26053972MNVGMN4074

